title: Celiac disease manifested during the treatment of chronic hepatitis C by pegylated alpha interferon and ribavirin.
abstract: Authors report a case of patient suffering from haemophilia A and hepatitis C virus infection acquired probably after blood transfusions and substitution factors application. He was treated with pegylated interferon alpha and ribavirin, with the development of malabsorption symptoms during the therapy. Celiac disease was established by histological, histochemical and serological examinations. oth, interferon alpha and ribavirin treatment as well as virus of hepatitis C may trigger coeliac disease in genetically predisposed individuals. The immunological mechanism of celiac disease include balance disruption between Th1 and Th2 immunological response with Th1 predominance. Only few similar cases have been published in the professional literature to date. Development of celiac disease during interferon alpha therapy with haemophilia A was not published until now (Fig. 3, Ref. 13).
authors.affiliation: 1st Department of Internal Medicine, University Hospital of L. Pasteur Kosice, Slovakia. lauragombosova@yahoo.com
authors.forename: L
authors.initials: L
authors.lastname: Gombosova
authors.forename: P
authors.initials: P
authors.lastname: Jarcuska
authors.forename: B
authors.initials: B
authors.lastname: Benova
authors.forename: M
authors.initials: M
authors.lastname: Benicky
authors.forename: I
authors.initials: I
authors.lastname: Lazurova
mesh_terms: D000328:Adult; D002446:Celiac Disease / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D006467:Hemophilia A / Q000150:complications; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b